Table 3 Distribution of hemoglobinopathies and MSP-2 based on EBV status < 6 months of age

Thalassemia

αα/αα

46

9 (19.6)

37 (80.4)

^b0.615

27 (58.7)

19 (41.3)

^a0.413

-α^3.7/αα

34

4 (11.8)

30 (88.2)

24 (70.6)

10 (29.4)

Sickle cell Status

Hb AA

62

10 (16.1)

52 (83.9)

^b1.000

37 (74.0)

25 (40.3)

^b0.249

Hb AS

17

3 (17.6)

14 (82.4)

13 (26.0)

4 (13.8)

G6PD Group A1

Viangchan 871G > A /Chinese 1024 C > T -Negative

9

3(30)

6 (66.7)

^b0.153

5 (6.2)

4 (4.9)

^b0.616

Viangchan 871G > A /Chinese 1024 C > T -Positive

72

10(14.1)

62 (86.1)

46 (56.8)

26 (32.1)

G6PD group A2

Mahidol 487G > A/Coimbra 592 C > T -Negative

5

0 (0)

5 (7.4)

^b0.407

3 (3.7)

2 (2.5)

^b0.442

Mahidol 487G > A/Coimbra 592 C > T -Positive

76

13 (16.9)

63 (82.9)

48 (59.3)

28 (34.6)

G6PD group B

Union 1360 C > T/Kaiping 1388G > A)-Negative

15

1(6.7)

14 (93.3)

^b0.197

5 (6.2)

10 (12.3)

^a0.494

Union 1360 C > T /Kaiping 1388G > A)-Positive

66

12(18.2)

54 (81.8)

41 (50.6)

25 (30.9)

G6PD African A-

A-

19

6 (31.6)

13 (68.4)

^a0.084

14 (17.5)

5 (6.3)

^a0.280

A

55

7(12.7)

48 (87.3)

31 (38.8)

24 (30.0)

B

6

0 (0.0)

6 (100)

5 (6.3)

1 (1.3)

MSP-2

FC27 Negative

50

7 (14)

43 (86)

^b0.914

31 (59.6)

19 (65.5)

^a0.814

FC27 Positive

20

3 (15)

17 (85)

13 (25.0)

7 (24.1)

3D7 Negative

29

4 (13.8)

25 (86.2)

^b0.921

16 (30.8)

13 (44.8)

^a0.263

3D7 Positive

41

6 (14.6)

35 (85.4)

28 (68.3)

13 (31.7)